Aspen Group Inc. (ASPU)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Aspen Aerogels: Green Shoots Fail To Truly Impress Investors
Aspen Aerogels delivered sequential revenue and EBITDA improvement, with Q2 revenues topping guidance and Q3 outlook signaling further recovery. Thermal Barrier sales rebounded sequentially, especially in Europe, but remain pressured by regulatory shifts and evolving battery technologies. ASPN's EBITDA break-even threshold lowered to $175 million in annual revenue, reflecting cost discipline and operational progress despite fire-related disruptions.
Aspen Aerogels Reminds Us Materials Science Can Be Cool, Especially If EVs Are Hot
Consider the kinds of endeavors that capture our interest. My theory: They often relate to things we can see, understand and admire in day to day life. This is probably why more children aspire to be actors than, say, accountants, and why investors gravitate more to AI or fancy tech, than say, materials science.
Aspen Aerogels Q2 Earnings Call Highlights
Aspen Aerogels NYSE: ASPN said it expects a sharp sequential increase in revenue and adjusted EBITDA in the third quarter, supported by energy-industrial project deliveries, rising General Motors EV production and expanding European demand for its PyroThin thermal barriers.
JPMorganChase and Amazon Back Aspen Institute Drive Against Scams
The Aspen Institute Financial Security Program (Aspen FSP) has launched a new effort focused on reducing the scale and severity of scams affecting Americans.
Aspen Aerogels Q1 Earnings Call Highlights
Aspen Aerogels NYSE: ASPN said it expects revenue to improve sequentially through 2026 despite a first-quarter sales decline, a temporary shutdown at its East Providence, Rhode Island, manufacturing facility and continued volatility in electric vehicle-related demand.
Aspen Insurance: Preferreds To Continue Post Merger
Aspen Insurance Holdings is being acquired by Sompo Holdings for $37.50/share, a 35.6% premium, with common shares to be delisted post-merger. AHL.PR.D preferred shares offer a 7.1% yield and will convert to successor company preferreds, but face potential post-merger liquidity risk if not relisted. AHL's focused strategy improved its combined ratio to 86.8% in Q3 2025, with underwriting and capital markets income both showing strong year-over-year growth.
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa
South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes and obesity drug, Mounjaro, for chronic weight management in the country.
Aspen Aerogels: Still Many Questions After A Big Setback
Aspen Aerogels has stabilized after a dramatic boom-bust cycle that in itself was driven by EV market volatility and overexpansion. Revenue and EBITDA guidance suggest modest improvement, but near-term growth remains muted and heavily reliant on GM as a key customer. Long-term risks persist from EV market uncertainty, competition, and potential technological shifts like solid-state batteries reducing insulation demand.
Aspen Aerogels: Still Cheap Despite +32% Over The Last Month
Aspen Aerogels' PyroThin technology is driving growth, with strong OEM contracts and a massive addressable market in EV thermal barriers. Despite recent revenue and margin softness, cost-cutting and capital-light manufacturing position ASPN for margin expansion and improved profitability. The energy industrial segment remains a stable, high-margin contributor, balancing volatility in the EV business and supporting long-term growth.
Aspen Insurance Holdings: Is 7% Good Enough?
Aspen Insurance Holdings Limited preferreds offer a 7%+ yield but come with a Ba1 (non-investment grade) rating and non-cumulative, fixed dividends. Compared to peers, AHL preferreds have higher risk and do not stand out for yield or tax advantages, despite trading below par. Current spreads versus Treasuries are not compelling, and better risk-adjusted yields exist elsewhere in the fixed-income market.
Aspen: Navigating Profit In A Hardening Insurance Market
Aspen has demonstrated strong underwriting profitability and value creation despite industry headwinds, supported by a hardening insurance market and disciplined capital allocation. The company's integrated 'One Aspen' approach and ACM platform differentiate it, enabling bespoke risk solutions and stable, growing fee income from third-party capital. Aspen continues to generate economic profit with solid free cash flow and an attractive valuation, with the market pricing in conservative growth assumptions.
Aspen Aerogels: The Shock Continues
Aspen Aerogels shifted focus from industrial insulation to EVs in recent years, driving initial growth, but its fortunes have reversed due to slow EV adoption. Despite impressive revenue growth in 2024, the company halted a major plant project due to weaker long-term EV demand, impacting investor confidence, and incurred huge losses. First quarter 2025 results showed a significant revenue drop and a massive GAAP loss, with no quick avail in sight.
